Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Imprimis Pharmaceuticals Inc Announces Pricing Of Public Offering Of 1,840,000 Shares Of Common Stock


Thursday, 7 Feb 2013 07:42pm EST 

Imprimis Pharmaceuticals Inc announced the pricing of an underwritten public offering of 1,840,000 shares of its common stock at a price to the public of $5.25 per share, for gross proceeds of approximately $9.66 million. The net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $8.13 million. Subject to customary conditions, Imprimis expects to close the sale of its common stock on or about February 13, 2013. MDB Capital Group, LLC is the sole book-running manager of the offering and Aegis Capital Corp. is acting as co-manager. Imprimis has granted the underwriters a 45-day option to purchase up to an additional 276,000 shares of Imprimis' common stock to cover over-allotments, if any. 

Company Quote

8.15
0.04 +0.49%
25 Nov 2014